Vaxart (OTCMKTS:VXRT) Raised to Hold at Zacks Research

Posted by Brian Himes on Jul 11th, 2026

Vaxart (OTCMKTS:VXRT – Get Free Report) was upgraded by stock analysts at Zacks Research to a “hold” rating in a report released on Thursday,Zacks.com reports.

Vaxart Trading Down 0.2%

OTCMKTS:VXRT traded down $0.00 during mid-day trading on Thursday, hitting $0.55. The stock had a trading volume of 331,273 shares, compared to its average volume of 314,656. The company has a 50 day simple moving average of $0.61 and a 200-day simple moving average of $0.62. The stock has a market capitalization of $132.59 million, a price-to-earnings ratio of 3.64 and a beta of 1.09. Vaxart has a 52 week low of $0.30 and a 52 week high of $0.84.

Vaxart (OTCMKTS:VXRT – Get Free Report) last posted its earnings results on Thursday, May 7th. The biotechnology company reported $0.02 EPS for the quarter, hitting the consensus estimate of $0.02. The firm had revenue of $39.23 million during the quarter, compared to analysts’ expectations of $50.50 million. Vaxart had a net margin of 14.51% and a return on equity of 61.43%. As a group, equities research analysts anticipate that Vaxart will post -0.68 earnings per share for the current year.

Institutional Investors Weigh In On Vaxart

Several institutional investors have recently bought and sold shares of the stock. Invesco Ltd. grew its position in Vaxart by 93.1% in the 1st quarter. Invesco Ltd. now owns 146,366 shares of the biotechnology company’s stock valued at $60,000 after buying an additional 70,568 shares in the last quarter. Jones Financial Companies Lllp raised its position in shares of Vaxart by 276,364.7% during the 1st quarter. Jones Financial Companies Lllp now owns 478,284 shares of the biotechnology company’s stock worth $196,000 after buying an additional 478,111 shares in the last quarter. Goldman Sachs Group Inc. bought a new stake in shares of Vaxart during the 1st quarter worth about $31,000. Creative Planning acquired a new stake in shares of Vaxart in the 2nd quarter worth approximately $33,000. Finally, Marshall Wace LLP acquired a new stake in shares of Vaxart in the 2nd quarter worth approximately $794,000. Institutional investors and hedge funds own 18.05% of the company’s stock.

About Vaxart

(Get Free Report)

Vaxart, Inc is a clinical-stage biotechnology company pioneering the development of oral recombinant vaccines administered in tablet form. Leveraging a proprietary, room-temperature-stable platform, the company aims to simplify vaccine delivery while eliciting both systemic and mucosal immune responses. Its technology is based on the replication-defective adenovirus vector system, which encodes target antigens designed to protect against a range of infectious diseases without the need for injections or cold-chain logistics.

The company’s pipeline includes multiple vaccine candidates in various stages of development.